Inspire Medical Systems yesterday up-sized its initial public offering to $108 million, or some $124 million if the underwriters option is exercised in full.
Maple Grove, Minn.-based Inspire, which spun out from Medtronic (NYSE:MDT) in 2007, makes devices for treating obstructive sleep apnea. The company had said it planned to issue 5 million shares at $14 to $16 apiece, which would have fetched $75 million at the midpoint.
But in a regulatory filing yesterday, Inspire said it sold 6.75 million shares at $16 apiece and put an underwriters option on the table that’s worth another $16.2 million.
Inspire, which posted net losses of -$17.5 million on sales of $28.6 million last year, plans to list on the New York Stock Exchange under the INSP symbol. The flotation is slated to price next week.
The company developed a pacemaker-like system designed to stimulate nerves to keep airways open during sleep to treat obstructive sleep apnea. BofA Merrill Lynch and Goldman Sachs & Co are acting as underwriters for the offering, according to an SEC filing.
In November 2016, Inspire Medical closed a $37.5 million Series F round.